Search clinical trials for: ABT-SLV176

Total 4351 results

AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-I)

Endometriosis
AbbVie

Completed

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-II)

Endometriosis
AbbVie

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Atopic Dermatitis

United States, Norway, Puerto Rico
University of Wisconsin, Milwaukee
National Institute of Mental Health (NIMH)

Completed

Testing a New Therapy for Trichotillomania

Trichotillomania

United States
University of Alabama at Birmingham

Completed

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Brain Tumor

United States
Abbott

Completed

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Chronic Kidney Disease

China
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
AbbVie

Completed

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Psoriatic Arthritis
AstraZeneca

Completed

Interaction Between ABT-335, Rosuvastatin and Warfarin

Healthy

United States
Southern Europe New Drug Organization
Clinical Trial Unit Ente Ospedaliero Cantonale

Completed

Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer (S10PANI01)

Advanced Head and Neck Squamous Cancer
Yale University

Completed

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

CTCL

United States
AbbVie (prior sponsor, Abbott)

Completed

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Australia, Israel, Poland, Ukraine
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Healthy Female Subjects

United States
King Faisal University
Mansoura University

Completed

Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function

Lung Diseases | Esophageal Diseases

Egypt
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Multiple Sclerosis (MS)

United States, Canada
AbbVie
Genentech, Inc.

Completed

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Australia
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Small Cell Lung Carcinoma | Small Cell Lung Cancer

United States, Canada, United Kingdom
Kerry Rogers
Janssen Research & Development, LLC

Withdrawn

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Chronic Lymphocytic Leukemia | Loss of Chromosome 17p
Abbott

Completed

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

Hypogonadal Males

United States
AbbVie

Completed

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Lymphoblastic Lymphoma | Acute Lymphoblastic Leukemia (ALL)

United States, Australia
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Institute of Diabetes and Digestive and...

Completed

Development of Limited Contact CBT Treatment for IBS

IBS

United States
Abbott

Completed

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
National Cancer Institute (NCI)

Terminated

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditions

United States
AbbVie

Available

Expanded Access to Venetoclax

Multiple Myeloma | Non-Hodgkin's Lymphoma | Amyloidosis | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Plasma Cell Leukemia
AbbVie

Completed

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms (CisCP)

Chronic Pancreatitis

United States
Fondazione Italiana Linfomi - ETS

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

Italy
AbbVie

Completed

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
AbbVie

Withdrawn

Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer

Exocrine Pancreatic Insufficiency (EPI)
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
Autotelicbio

Recruiting

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Diabetes Mellitus, Type 2 | Essential Hypertension

Korea, Republic of
University of Roma La Sapienza

Not yet recruiting

A Prospective muLticEnter Registry in chrONic coronARy synDrOme (LEONARDO)

Coronary Artery Disease
Abbott Medical Devices

Completed

Abbott Next Generation Drug Eluting Stent 48mm Study (SPIRIT 48)

Coronary Artery Disease

United States, Australia, Taiwan
Children's Oncology Group
National Cancer Institute (NCI)

Completed

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States, Canada
Zimmer Biomet

Completed

G7 Acetabular System vs. Exceed ABT Acetabular System in THA (G7)

Rheumatoid Arthritis | Osteoarthritis Arthritis

Korea, Republic of
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus

United States, Germany, Mexico, Puerto Rico
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Mexico
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)

Chronic Myeloid Leukemia

France
AbbVie

Recruiting

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (ELASCI)

Spinal Cord Injury (SCI)

United States, Australia, Canada, Israel, Japan, Spain, Korea, Republic of
Frontier Biotechnologies Inc.

Unknown

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

HIV/AIDS

China
M.D. Anderson Cancer Center
Abbott

Completed

Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

Head and Neck Cancer

United States
AbbVie (prior sponsor, Abbott)
Neurocrine Biosciences

Completed

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Folliculogenesis

United States, Puerto Rico
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
AbbVie

Completed

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Japan

3

Subscribe